Literature DB >> 9311516

Airway deposition and airway effects of antiasthma drugs delivered from metered-dose inhalers.

R Pauwels1, S Newman, L Borgström.   

Abstract

Many different metered-dose inhalation devices are becoming available for the treatment of airway diseases. Each of these inhalers differs in its delivery characteristics. An assessment of the efficacy of drug delivery by these inhalers is essential, in view of their therapeutic use. A review of the literature on the relationship between airway deposition and airway effects of drugs delivered from metered-dose inhalers is presented. Nebulizers or spacers are not discussed. The effect of an inhaler depends on the characteristics of the inhaler and the inhalation manoeuvre performed by the patient. This review focuses on the influence of inhaler characteristics on the airway deposition and airway effects. Data from several studies show that there is a significant relationship between the amount of drug deposited in the airways and the airway effects of the drug. Studies on the relationship between airway deposition and airway effect have been troubled by methodological problems, such as the absence of multiple dose comparisons and the difficulty in obtaining steep dose-response curves. The techniques for measuring airway deposition of inhaled drugs, namely the scintigraphic and the pharmacokinetic method, are discussed and compared. The appropriate use of these techniques can help to define and compare the drug delivery characteristics of different devices, thus enabling inhaled therapy to be optimized.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9311516     DOI: 10.1183/09031936.97.10092127

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  19 in total

Review 1.  Can lung deposition data act as a surrogate for the clinical response to inhaled asthma drugs?

Authors:  S P Newman
Journal:  Br J Clin Pharmacol       Date:  2000-06       Impact factor: 4.335

Review 2.  Discriminating measures of bronchodilator drug efficacy and potency.

Authors:  H Buck; M Parry-Billings
Journal:  Br J Clin Pharmacol       Date:  2001-09       Impact factor: 4.335

3.  Administration of substances to laboratory animals: routes of administration and factors to consider.

Authors:  Patricia V Turner; Thea Brabb; Cynthia Pekow; Mary Ann Vasbinder
Journal:  J Am Assoc Lab Anim Sci       Date:  2011-09       Impact factor: 1.232

Review 4.  Deposition and effects of inhaled corticosteroids.

Authors:  Stephen P Newman
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

5.  Factors Determining In Vitro Lung Deposition of Albuterol Aerosol Delivered by Ventolin Metered-Dose Inhaler.

Authors:  Rajoshi Biswas; Nicola A Hanania; Ashutosh Sabharwal
Journal:  J Aerosol Med Pulm Drug Deliv       Date:  2017-02-03       Impact factor: 2.849

6.  Pharmacodynamic Studies to Demonstrate Bioequivalence of Oral Inhalation Products.

Authors:  Leslie Hendeles; Peter T Daley-Yates; Robert Hermann; Jan De Backer; Sanjeeva Dissanayake; Stephen T Horhota
Journal:  AAPS J       Date:  2015-02-26       Impact factor: 4.009

Review 7.  Scientific Rationale for Determining the Bioequivalence of Inhaled Drugs.

Authors:  Omar S Usmani; Mathieu Molimard; Vaibhav Gaur; Jaideep Gogtay; Gur Jai Pal Singh; Geena Malhotra; Eric Derom
Journal:  Clin Pharmacokinet       Date:  2017-10       Impact factor: 6.447

8.  Prevalence of Low Peak Inspiratory Flow Rate at Discharge in Patients Hospitalized for COPD Exacerbation.

Authors:  Gulshan Sharma; Donald A Mahler; Valerie M Mayorga; Kathleen L Deering; Oing Harshaw; Vaidyanathan Ganapathy
Journal:  Chronic Obstr Pulm Dis       Date:  2017-07-15

9.  Pharmacokinetics and systemic activity of fluticasone via Diskus and pMDI, and of budesonide via Turbuhaler.

Authors:  L Thorsson; S Edsbäcker; A Källén; C G Löfdahl
Journal:  Br J Clin Pharmacol       Date:  2001-11       Impact factor: 4.335

10.  Randomised placebo controlled trial of beta agonist dose reduction in asthma.

Authors:  T W Harrison; J Oborne; P J Wilding; A E Tattersfield
Journal:  Thorax       Date:  1999-02       Impact factor: 9.139

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.